62.85 0.00 (0.00%)
After hours: 4:58PM EDT
|Bid||62.84 x 800|
|Ask||62.86 x 1000|
|Day's range||62.41 - 63.41|
|52-week range||56.58 - 72.81|
|Beta (3Y monthly)||0.80|
|PE ratio (TTM)||19.92|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
In 1989 Stanley Bergman was appointed CEO of Henry Schein, Inc. (NASDAQ:HSIC). First, this article will compare CEO...
Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts. However, intense competition remains a woe.
Major drug wholesalers and retailers facing a massive lawsuit for allegedly fostering the nation's opioid crisis asked the judge hearing the case to recuse himself on Saturday. The companies argued in a court filing that U.S. District Judge Dan Polster, who is hearing the case in a federal court in Cleveland, Ohio, had made statements in court indicating that he was not impartial in the case and improperly pushed the companies to settle without going to trial. The companies said that Judge Polster had also made improper public comments about the case, including to reporters.
Paylocity, Macy's, Henry Schein, DENTSPLY and Patterson Companies highlighted as Zacks Bull and Bear of the Day
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Henry Schein (HSIC) delivered earnings and revenue surprises of 1.20% and -1.26%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Investing.com - Henry Schein reported second quarter earnings that beat analysts' expectations on Tuesday and revenue that fell short of forecasts.
Henry Schein (HSIC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GW Pharmaceuticals (GWPH) is witnessing a solid new patient recruitment for Epidolex and a huge number of physicians are recommending the same in their prescriptions.
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Better-than-expected performance at Technology & Equipment and growth in emerging markets are likely to aid DENTSPLY SIRONA (XRAY) in Q2 earnings.
Better-than-expected performance at Pharmaceutical Distribution and higher revenues are likely to aid AmerisourceBergen (ABC) in Q3 earnings.
Does the July share price for Henry Schein, Inc. (NASDAQ:HSIC) reflect what it's really worth? Today, we will estimate...